The effect of low advanced glycation end product (AGEs) diet on bone health and cardio-metabolic parameters in obese postmenopausal women: a randomized controlled trial

The effect of low advanced glycation end product (AGEs) diet on bone health and cardio-metabolic parameters in obese postmenopausal women: a randomized controlled trial - AGEs

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00034643

Enrollment

Registered

2024-07-16

Start date

2024-05-22

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E66

Interventions

Group 1: Low AGEs diet (n=40) Group 2: Standard AGEs diet (n=40)

Eligibility

Sex/Gender

Female

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: BMI = 25.0 kg/m², menopause: at least 12 months prior to study enrolment

Exclusion criteria

Exclusion criteria: Menopause before the age of 40 years, previously diagnosed osteoporosis or other bone diseases, taking medications that affect bone metabolism, taking hormone replacement therapy, taking calcium or vitamin K supplements in the last 3 months, diagnosed acute or chronic autoimmune diseases, inflammatory diseases, infectious diseases, viral, bacterial or parasitic infections, malignant neoplastic disease treated with chemo- or radiotherapy within the last 5 years, acute and chronic kidney and liver diseases, underactive or overactive parathyroid glands.

Design outcomes

Primary

Measure	Time frame
Bone mineral density (BMD), bone mineral content (BMC), osteocalcin, bone-specific alkaline phosphatase (BSAP), cross-linked C-terminal telopeptide of type I collagen (CTX-I) will be assessed before and after the 12-month intervention period.	—

Secondary

Measure	Time frame
Fasting glucose and insulin, homeostasis model assessment of insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), asymmetric dimethylarginine (ADMA), soluble vascular cell adhesion molecule-1 (sVCAM-1), high-sensitivity C-reactive protein (hs-CRP), AGEs, 25-hydroxyvitamin D (25(OH)D), systolic (SBP) and diastolic blood pressure (DBP), body weight, waist and hip circumference, body mass index (BMI), percentage of fat (%FM), free-fat mass (%FFM) and visceral adipose tissue (VAT) will be assessed before and after the 12-month intervention period.	—

Measure

Time frame

Fasting glucose and insulin, homeostasis model assessment of insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), asymmetric dimethylarginine (ADMA), soluble vascular cell adhesion molecule-1 (sVCAM-1), high-sensitivity C-reactive protein (hs-CRP), AGEs, 25-hydroxyvitamin D (25(OH)D), systolic (SBP) and diastolic blood pressure (DBP), body weight, waist and hip circumference, body mass index (BMI), percentage of fat (%FM), free-fat mass (%FFM) and visceral adipose tissue (VAT) will be assessed before and after the 12-month intervention period.

—

Countries

Poland

Contacts

Public ContactMalgorzata Jamka

Department of Pediatric Gastroenterology and Metabolic DiseasesPoznan University of Medical Sciences

mjamka@ump.edu.pl+48 61 849 14 32

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026